医学
怀孕
重症监护医学
疾病
疾病管理
产科
心脏病学
内科学
遗传学
生物
帕金森病
作者
Julie De Backer,Kristina H. Haugaa,Nina E. Hasselberg,Michèle de Hosson,Margarita Brida,Silvia Castelletti,Matthew Cauldwell,Elisabetta Cerbai,Lia Crotti,Natasja M.S. de Groot,Mette‐Elise Estensen,Eva Goossens,Bernhard Haring,Donata Kurpas,Carmel M. McEniery,Sanne A. E. Peters,Amina Rakisheva,Antonia Sambola,Oliver Schlager,Florian Schoenhoff
标识
DOI:10.1093/eurheartj/ehaf193
摘要
Cardiovascular disease (CVD) is a major cause of maternal mortality and morbidity. With these new Guidelines we wish to provide updated evidence-based guidance for patients and caregivers. Reducing maternal mortality and morbidity is a key priority of the World Health Organization (WHO). In managing maternal and foetal health, it is essential to balance the risks and benefits of maternal and foetal therapeutic needs. Due to the scarcity of prospective or randomized studies within this field, which often cannot be performed for ethical reasons, most recommendations in these Guidelines are based on evidence level C. Consequently, there is an ongoing need for more registries, such as the Registry of Pregnancy and Cardiac Disease (ROPAC) and the European Surveillance of Congenital Anomalies network, and prospective studies to enhance our understanding in this area.
科研通智能强力驱动
Strongly Powered by AbleSci AI